Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval a...
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo
ZURICH - Roche’s Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb. The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations, Roche said on Wednesday.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA bowed to industry for decades as alarms were sounded over talcSince the 1970s, the FDA downplayed health concerns about talc in powders and cosmetics, deferring again and again to manufacturers, documents show.
Leer más »
Senate panel backs Trump’s pick to run FDAThe full Senate will vote on Hahn’s nomination before he can become FDA commissioner.
Leer más »
Senate panel backs Trump’s pick to run FDAThe full Senate will vote on Hahn’s nomination before he can become FDA commissioner.
Leer más »
Apple Pie Moonshine RecipeFor the holidays, Vivian Howard always receives a few jars of ‘Apple Pie’ cocktail as gifts.
Leer más »
Influencer Miroslava Duma Reveals She Has a Rare Lung DiseaseMiroslava Duma Reveals She Was Diagnosed with Rare Lung Disease
Leer más »